No benefit found for use of probiotic Bifidobacterium breve in very preterm children to prevent death, late-onset sepsis, or necrotising enterocolitis

The results of a randomised controlled trial, published today in The Lancet, show that, despite being safe to administer, there is no benefit in using the probiotic Bifidobacterium breve (BBG-001) to prevent late-onset sepsis or necrotising enterocolitis in very preterm children. This new study, funded by the NIHR HTA Programme contradicts previous work showing potential...
Source: NIHR Evaluation, Trials and Studies News - Category: American Health Source Type: news